These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24767472)

  • 1. Shining a light in the black box of orphan drug pricing.
    Picavet E; Morel T; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2014 Apr; 9():62. PubMed ID: 24767472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysing criteria for price and reimbursement of orphan drugs in Spain.
    Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
    Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variables affecting pricing of orphan drugs: the Italian case.
    Jommi C; Listorti E; Villa F; Ghislandi S; Genazzani A; Cangini A; Trotta F
    Orphanet J Rare Dis; 2021 Oct; 16(1):439. PubMed ID: 34666819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
    Kawakami A; Masamune K
    Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reimbursement of orphan drugs in Belgium: what (else) matters?
    Picavet E; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.
    Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saving orphan drug legislations: misconceptions and clarifications.
    Hyry HI; Cox TM; Roos JC
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of orphan drug prices in Europe.
    Young KE; Soussi I; Hemels M; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1297886. PubMed ID: 28473887
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.